Mabion (FRA:272) Long-Term Debt : €0.05 Mil (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Mabion Long-Term Debt?

Mabion's Long-Term Debt for the quarter that ended in Dec. 2023 was €0.05 Mil.

Mabion's quarterly Long-Term Debt declined from Jun. 2023 (€0.07 Mil) to Sep. 2023 (€0.06 Mil) and declined from Sep. 2023 (€0.06 Mil) to Dec. 2023 (€0.05 Mil).

Mabion's annual Long-Term Debt increased from Dec. 2021 (€0.05 Mil) to Dec. 2022 (€0.09 Mil) but then declined from Dec. 2022 (€0.09 Mil) to Dec. 2023 (€0.05 Mil).

Mabion Long-Term Debt Historical Data

The historical data trend for Mabion's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mabion Long-Term Debt Chart

Mabion Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Long-Term Debt

Get a 7-Day Free Trial

0.14

0.05

0.09

0.05

Mabion Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Long-Term Debt	Get a 7-Day Free Trial															0.09	0.08	0.07	0.06	0.05

Mabion (FRA:272) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Mabion Long-Term Debt Related Terms

Thank you for viewing the detailed overview of Mabion's Long-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Mabion (FRA:272) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mabion SA (FRA:272) » Definitions » Long-Term Debt

Comparable Companies

Traded in Other Exchanges

MAB:Poland

Address

ul. Gen. Mariana Langiewicza 60, Konstantynow Lodzki, POL, 95-050

Website

https://www.mabion.eu

Mabion SA is a Polish biotechnology company focused on developing and launching modern biotechnology drugs based on monoclonal antibody technology. The drugs developed by the company are targeted treatments, characterized by the drug's ability to recognize the factor causing cancer and interact with this factor only. The company is working on the development of its main priority drug, referred to as the MabionCD20 drug. The therapeutic uses of MabionCD20 are for Non-Hodgkin's lymphoma, Leukemia, and Rheumatoid Arthritis.

Mabion (FRA:272) Headlines

No Headlines